This is a single arm Phase Ib/II, open label, safety, pharmacokinetic, pharmacodynamics and
efficacy study of ONC201 in combination with Opdivo (Nivolumab) in adult patients with
metastatic colorectal cancer, for whom no standard therapy is available. This study will
enroll adult patients with metastatic colorectal cancer who progressed after at least two
lines of therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Khaldoun Almhanna
Collaborators:
Bristol-Myers Squibb Brown University Oncoceutics, Inc. Rhode Island Hospital